April 21, 2020
Schwendinger M et al. J Infect Dis 2020;jiaa121.
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus
You might also be interested by
Brochures
High Performance Technologies for Cytokine Measurement
November 8, 2021
Immune Monitoring
More infoInfographics
Advance Your Cell Therapy with Cross-Platform Capabilities
November 5, 2021
Histopathology
More info